The results of the present study demonstrated that MEF2A plays a role in the progression of CRC by upregulating the expression of ZEB2 and β-catenin to enhance the EMT and the activity of the WNT/β-catenin signaling pathway. Here, MEF2A is linked to colorectal carcinoma.